PDF(Pubmed)
Abstract：
OBJECTIVE: To observe the effect of Butylphthalide soft capsules on improving cognitive function, activity of daily living, and dementia-related factors of elderly patients with Parkinson\'s disease dementia (PDD) during the coronavirus disease 2019 (COVID-19) pandemic.
METHODS: The clinical data of 126 elderly patients with PDD admitted to the Second Affiliated Hospital of Zhengzhou University during the COVID-19 pandemic were analyzed retrospectively. Patients were assigned to a control group (conventional clinical treatment, n=50) and a research group (conventional clinical treatment combined with Butylphthalide soft capsules, n=76). The clinical response, clinical symptoms, cognitive function, activity of daily living (ADL), cerebral blood flow velocity, serum inflammatory factors, oxidative stress indices, neurotrophic factors, dementia-related factors, and drug safety were analyzed and compared between the two groups.
RESULTS: The overall response rate was significantly higher in the research group than in the control group (97.37% vs. 84.00%, P=0.017). After treatment, the clinical symptom-based scores and levels of serum inflammatory factors, malondialdehyde, and Parkinson disease protein 7 were significantly lower in the research group than in the control group (all P<0.001); the cognitive function and ADL scores, cerebral blood flow velocities, and levels of catalase, glutathione peroxidase, superoxide dismutase, neurotrophic factors, and neurotrophin-3 were significantly higher in the research group (all P<0.001). The incidence of adverse reactions was comparable between the two groups (4.00% vs. 6.58%, P=0.825).
CONCLUSIONS: Butylphthalide soft capsules have a definite effect and good safety in elderly patients with PDD during the COVID-19 pandemic.
METHODS: The clinical data of 126 elderly patients with PDD admitted to the Second Affiliated Hospital of Zhengzhou University during the COVID-19 pandemic were analyzed retrospectively. Patients were assigned to a control group (conventional clinical treatment, n=50) and a research group (conventional clinical treatment combined with Butylphthalide soft capsules, n=76). The clinical response, clinical symptoms, cognitive function, activity of daily living (ADL), cerebral blood flow velocity, serum inflammatory factors, oxidative stress indices, neurotrophic factors, dementia-related factors, and drug safety were analyzed and compared between the two groups.
RESULTS: The overall response rate was significantly higher in the research group than in the control group (97.37% vs. 84.00%, P=0.017). After treatment, the clinical symptom-based scores and levels of serum inflammatory factors, malondialdehyde, and Parkinson disease protein 7 were significantly lower in the research group than in the control group (all P<0.001); the cognitive function and ADL scores, cerebral blood flow velocities, and levels of catalase, glutathione peroxidase, superoxide dismutase, neurotrophic factors, and neurotrophin-3 were significantly higher in the research group (all P<0.001). The incidence of adverse reactions was comparable between the two groups (4.00% vs. 6.58%, P=0.825).
CONCLUSIONS: Butylphthalide soft capsules have a definite effect and good safety in elderly patients with PDD during the COVID-19 pandemic.
摘要：
目的：观察丁苯酞软胶囊对认知功能的改善作用。日常生活活动，2019年冠状病毒病（COVID-19）大流行期间老年帕金森病痴呆（PDD）患者的痴呆相关因素。
方法：回顾性分析郑州大学第二附属医院收治的126例老年PDD患者的临床资料。患者被分配到对照组(常规临床治疗,n=50)和研究组(常规临床治疗联合丁苯酞软胶囊,n=76)。临床反应，临床症状,认知功能,日常生活活动(ADL)，脑血流速度,血清炎症因子,氧化应激指数，神经营养因子，痴呆相关因素,分析比较两组患者的用药安全性。
结果：研究组的总有效率明显高于对照组（97.37%vs.84.00%,P=0.017)。治疗后,临床症状积分和血清炎症因子水平,丙二醛，与对照组相比,研究组帕金森病蛋白7显著降低(均P<0.001);脑血流速度,和过氧化氢酶的水平，谷胱甘肽过氧化物酶,超氧化物歧化酶,神经营养因子，和神经营养因子-3在研究组中显著高于对照组(均P<0.001)。两组不良反应发生率相当（4.00%vs.6.58%，P=0.825)。
结论：丁苯酞软胶囊治疗COVID-19大流行期间老年PDD患者疗效确切，安全性好。
方法：回顾性分析郑州大学第二附属医院收治的126例老年PDD患者的临床资料。患者被分配到对照组(常规临床治疗,n=50)和研究组(常规临床治疗联合丁苯酞软胶囊,n=76)。临床反应，临床症状,认知功能,日常生活活动(ADL)，脑血流速度,血清炎症因子,氧化应激指数，神经营养因子，痴呆相关因素,分析比较两组患者的用药安全性。
结果：研究组的总有效率明显高于对照组（97.37%vs.84.00%,P=0.017)。治疗后,临床症状积分和血清炎症因子水平,丙二醛，与对照组相比,研究组帕金森病蛋白7显著降低(均P<0.001);脑血流速度,和过氧化氢酶的水平，谷胱甘肽过氧化物酶,超氧化物歧化酶,神经营养因子，和神经营养因子-3在研究组中显著高于对照组(均P<0.001)。两组不良反应发生率相当（4.00%vs.6.58%，P=0.825)。
结论：丁苯酞软胶囊治疗COVID-19大流行期间老年PDD患者疗效确切，安全性好。
